Latest news with #DimitrisMoulavasilis
Newsweek
23-07-2025
- Health
- Newsweek
How the Future of AI Health Care is Taking Shape in the Middle East
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. For a look at how the health care of the future will be shaped by artificial intelligence and data, Abu Dhabi is a good start. The genetic makeup of most of the local population has been sequenced, allowing anyone's high risk of disease to be detected — and action to be taken — long before symptoms appear. Apps help patients navigate their care, with plans underway to connect them to everything from data delivered by wearable devices to medical records as well as to their doctors. "We use AI to predict conditions and improve medical outcomes and by improving outcomes, we're reducing hospitalization costs, reducing costs for the system," said Dimitris Moulavasilis, the chief executive of M42, a global health care company headquartered in the capital of the United Arab Emirates that underpins the health system there and is expanding rapidly abroad. "We're using genomics data to create population programs, which, again predict conditions, keep people healthy and we are using digital to organize health systems." "I think there is a wish across the globe that we should be able to improve the care delivered and reduce the cost. So how we can move from a reactive, episodic sick care where we are today." Dimitris Moulavasilis, CEO of Abu Dhabi-headquartered global health company M42 Dimitris Moulavasilis, CEO of Abu Dhabi-headquartered global health company M42 Courtesy of M42 Moulavasilis noted that health care costs vary from 7 to 8 percent of GDP in Eastern Europe to as high as 17 percent in the United States, but the costs are growing faster than economic growth rates everywhere. He said some of the biggest beneficiaries of data-driven and AI-powered health care would be in the less wealthy countries of the Global South that are starting from a lower base and can build their health systems in a more effective way. Personalized Treatments "Data plays a role as AI allows for personalized treatments, which allows patients to get treated, or you may predict conditions and patients might not get sick, and you can avoid the potential disease before it happens," he said, adding that it was also important considering increasing longevity. "People want to have a longer health span, not necessarily 200 years, but to live healthily until the end of their biological lives." M42 is already the largest health care group in the Middle East and serves some 15 million patients worldwide with operations in 27 countries. Its revenues have grown five times in the past seven years. M42 highlights examples of specific patients who have already been helped — such as a 40-year-old Emirati woman who was identified as having a 100 percent chance of thyroid cancer because of a gene mutation. She was treated straight away. Then there was the eight-year-old with vision loss, which was again pinned down to a gene mutation and treatment provided. "In Abu Dhabi, we have digitalized all the system. Digitalizing the system is not just applying some technologies, it is designing the systems and applying them. We are the engine behind the health information exchange," Moulavasilis said. M42 has an advantage being based in a center with a commitment to high-tech investment and to becoming a base for research, as well as with possibly the world's most extensive genome program by percentage of people covered — with more than 800,000 of 1.3 million Emiratis already sequenced and the number rising quickly. M42 runs the program in partnership with the Department of Health. Danat Al Emarat Hospital in Abu Dhabi Danat Al Emarat Hospital in Abu Dhabi M42 "They have the metrics, the people, the sophistication, and they are embracing all these new technologies, so we may try to deploy new models of care here, which then, upon the proof of the efficiency and outcomes we may expand globally," Moulavasilis said. "Because we have now all these amazing data sets, we have developed a trusted research environment that with the right privacy for the patient and keeping the data in a sovereign environment, we can extract insights and we can make collaborative research with pharma companies to create new targeted drugs and create new value from the life science space," Moulavasilis said. Genome Database For its genome database, it is recruiting patients across different sectors and genders to make its data sets fully representative, with models trained on different nationalities. At the same time, respect is paid to protecting individuals' and countries' rights to data privacy. M42's operations extend much further than Abu Dhabi. Through acquisitions and organic growth, it now has more than 480 facilities in 26 countries and over 20,000 employees. It foresees annual growth in the future at around 8 to 10 percent. Although M42 is not yet in the United States, it is investigating opportunities for investment there. It is already in most European countries and has a significant presence in Latin America, including Brazil and Chile. It also has a major presence close to home in Saudi Arabia and the Gulf countries. In Uzbekistan, it is collaborating and exploring opportunities for a strategic partnership on the Uzbek Genome Program. "The Global South really is an important space for expansion," Moulavasilis said, particularly after the acquisition of kidney-care provider Diaverum. "We are in discussion with many countries, particularly the Global South." M42's biggest challenge is not technology, it is human nurses and physicians, Moulavasilis said. There again, however, AI helps all to work more effectively. "As the population grows and ages, there's a big amount of nurses who the global national health systems lack today," he said. "Now we're privileged to be perceived as employees of choice because of the use of digital and AI, so nurses can be always very much productive, focusing what they are trained to do like provide care, as opposed to liaise with all the bureaucratic and the routine, non-valuable, mundane activities."
Zawya
09-07-2025
- Business
- Zawya
M42, GE HealthCare join forces to advance AI-Enabled Patient Care
M42, a global health leader powered by technology, artificial intelligence and genomics, will collaborate with GE HealthCare, a global innovator in medical technology, pharmaceutical diagnostics and integrated, cloud-first AI-enabled digital solutions, to enhance diagnostic precision and deliver more personalised patient outcomes, marking a significant step forward in the future of smart healthcare in the UAE. M42 and GE HealthCare will harness their combined strengths in advanced AI-powered solutions and explore collaborative go-to-market initiatives to deliver smarter, more connected healthcare in the region, with a focus on improving both clinical and operational efficiency. Leveraging M42's advanced AI, data and technology platforms alongside GE HealthCare's deep expertise in medical technology and product development, this collaboration will focus on co-developing innovative solutions to tackle pain points in healthcare systems and help support business and operational outcomes. By integrating AI with multimodal data analysis, M42 and GE HealthCare aim to accelerate product development and further position the region as a growing hub for life sciences innovation. Dimitris Moulavasilis, Group Chief Executive Officer at M42, said, 'Our collaboration with GE HealthCare is another step forward in M42's journey to disrupt traditional healthcare systems and positively impact people. By combining our strengths, we will be developing and deploying tech-enabled solutions to tackle the toughest challenges in the healthcare sector, delivering real, measurable outcomes for both patients and health systems. Together, we aren't just reimagining the future of precision medicine and smart care; we're building it here in the UAE and scaling it to the world.' Konstantinos Deligiannis, EAGM (Eurasian and African Growth Markets), President of GE HealthCare, added, 'We are committed to driving precision care through innovation and collaboration. Our collaboration with M42 represents a powerful convergence of advanced AI, data, and clinical expertise, and is a testament to our shared vision of delivering smarter, more connected healthcare solutions that improve outcomes for patients everywhere.' Leveraging the UAE's innovation-friendly ecosystem, this partnership reflects the country's ambition to lead in global health innovation by advancing world-class, patient-centered care. In partnering with a global health tech giant, M42 continues to progress smarter, more personalised care for communities in the UAE and beyond. M42's Diaverum business has taken 30 years of dialysis know-how to develop an AI-powered digital platform that not only reduces hospital stays, but has decreased the mortality rate, predicting thrombotic events before they occur. M42 has also developed and deployed Med42 LLM model, a large language model designed for clinical use cases and available for research use as an open-source solution. The company's AIRIS-TB conducts 2,000 AI-powered chest X-ray examinations daily to screen for tuberculosis against 200 conducted via conventional methods.
Zawya
07-05-2025
- Business
- Zawya
M42 appoints Dimitris Moulavasilis as Group CEO
Abu Dhabi, 6 May 2025: M42, a global health leader powered by artificial intelligence (AI), technology, and genomics, is pleased to announce the appointment of Dimitris Moulavasilis as the company's new Group Chief Executive Officer, effective immediately. This change comes as Hasan Jasem Al Nowais transitions from his role to continue as a member of M42's Board after a long and successful tenure leading M42 and, previously, Mubadala Health. Mr. Moulavasilis brings a wealth of experience to the role as a trusted leader within the M42 ecosystem. He served as Chief Executive Officer (CEO) of M42's Global Patient Care platform, a central component of M42's mission to transform healthcare on a global scale, and as CEO of Diaverum, a global renal care provider acquired by M42 in 2023. Before joining Diaverum in 2018, he was the Group Chief Executive Officer at Affidea, a leading European provider of imaging, outpatient and cancer care services. With deep institutional knowledge and a proven track record of operational leadership, innovation, digital transformation and growth, Mr. Moulavasilis' appointment ensures a seamless transition and continued momentum for M42. The leadership transition follows a milestone chapter in M42's journey. Having led Mubadala Health after forming it as chief executive officer, including the acquisition of a 60 per cent stake in United Eastern Medical Services (UEMedical), Mr. Al Nowais was a founding figure behind the creation of M42 with the merger of Mubadala Health and G42 Healthcare in 2022. He has since played a defining role in shaping M42 into the AI-powered global health leader it is today, operating in 26 countries. Under his leadership, M42 has grown 5x in seven years, expanding internationally with the acquisition of Diaverum in 2023 and through organic growth strategies in key markets; entering local and global partnerships; and, delivering exceptional patient outcomes, with numerous UAE and regional firsts in care. Peng Xiao, Chairman of M42 and Group Chief Executive Officer of G42, said: 'Building on the strong foundation established by Hasan, we are now entering the next chapter of M42's journey. I want to sincerely thank Hasan for his visionary leadership and unwavering dedication in shaping M42 into the powerhouse it is today. Looking ahead, we are excited to work with Dimitris, a seasoned leader with global experience, strategic depth, and a passion for innovation. His appointment marks an exciting new phase for M42 as we continue to advance the frontiers of healthcare through technology and world-class clinical excellence.' Under Mr. Moulavasilis' leadership, M42 will remain firmly focused on its purpose-driven mission and core values, continuing to pioneer healthcare innovation from the UAE to the world. His vision will guide M42 through the next phase of its strategic growth and expansion across existing and new global markets. Dimitris Moulavasilis, newly appointed Group CEO of M42, said: 'It is a privilege to be entrusted with writing the next chapter for M42. I am proud to build on the strong foundation laid by Hasan and the leadership team. Together with our people, partners and patients, we will continue to push the boundaries of healthcare innovation, expand our global footprint and disrupt traditional healthcare models to accelerate the shift from sickness to prevention and positively impact lives locally and globally.' Hasan Jasem Al Nowais, current Managing Director and Group Chief Executive Officer of M42 said: 'Over the past decade, we've built on the strong foundations at Mubadala Health to create a global health leader in M42, which has improved lives across borders and continues to make innovative strides to benefit all people, leaving no-one behind. I am confident that Dimitris will continue to drive this vision forward with the same passion, purpose and relentless pursuit of excellence. I have unwavering confidence in M42's strength and readiness for the next chapter. With a strong, integrated group structure and a deep leadership bench, M42 is exceptionally well positioned for the future. I look forward to supporting Dimitris' efforts and M42 as a member of its Board.' About M42 M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally. Established in 2022, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi. For media inquiries or interview opportunities, please contact: Mazar Masud Senior Director, Global Corporate Communications, M42 E: mmasud@ M: +971 52 593 5926
